Drugs / B7H3-IRDye800CW
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06778603 | Jan 2024 → Jun 2025 overdue | osteosarcoma | Peking University People's Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B7H3-IRDye800CW | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06778603 ↗ |
| Route | Intravenous | “B7H3-IRDye800CW can accurately label OS areas after intravenous administration” PMID 38502871 ↗ Mar 2024 |